These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18215109)

  • 1. Market failure and the poverty of new drugs in maternal health.
    Fisk NM; Atun R
    PLoS Med; 2008 Jan; 5(1):e22. PubMed ID: 18215109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 3. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 4. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 5. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 6. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks in new drug development: approval success rates for investigational drugs.
    Dimasi JA
    Clin Pharmacol Ther; 2001 May; 69(5):297-307. PubMed ID: 11371997
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic possibilities of interference RNA.
    López Tricas JM
    Farm Hosp; 2012; 36(3):115-7. PubMed ID: 22137610
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantitative risk modelling for new pharmaceutical compounds.
    Tang Z; Taylor MJ; Lisboa P; Dyas M
    Drug Discov Today; 2005 Nov; 10(22):1520-6. PubMed ID: 16257374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic changes in the pregnant woman.
    Blackburn S
    J Perinat Neonatal Nurs; 2012; 26(1):13-4. PubMed ID: 22293637
    [No Abstract]   [Full Text] [Related]  

  • 13. Geriatric medications in the pipeline.
    Beary JF
    Health Aff (Millwood); 1990; 9(3):157-60. PubMed ID: 2227774
    [No Abstract]   [Full Text] [Related]  

  • 14. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.
    Gagnon MA; Lexchin J
    PLoS Med; 2008 Jan; 5(1):e1. PubMed ID: 18177202
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
    Tay-Teo K; Ilbawi A; Hill SR
    JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing attrition in drug development: smart loading preclinical safety assessment.
    Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
    Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of drug metabolism and pharmacokinetics for new drug development.
    Kim YG; Kang KW
    Arch Pharm Res; 2011 Nov; 34(11):1769-71. PubMed ID: 22139678
    [No Abstract]   [Full Text] [Related]  

  • 20. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
    Bender S; Flicker L; Rhodes R
    Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.